ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

MR-130A-01

A development code. Also written as “MR-130A-01 Transdermal patch” and “MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)”.

Its studies are led by Viatris.

Furthest: phase 2, since May 8, 20232 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris21 open or runningphase 2since May 8, 2023May 8, 2023Nov 30, 2026phase 2 · NCT07365904

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2023First study: phase 2 study in ContraceptionFirst studyNCT06048536 · 168 enrolled · Germany
  2. Sep 8, 2025Phase 2 study in ContraceptionNCT07365904 · 60 planned · Germany

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in ContraceptionNCT07365904

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07365904Contraception · Germany2RecruitingNov 30, 202660
NCT06048536Contraception · Germany2CompletedJan 18, 2024168

How it is read

Names in the registry

  • “MR-130A-01 Transdermal patch”, 4 entries
  • “MR-130A-01 contraceptive transdermal patch, containing norelgestromin (NGMN)”, 1 entry

Codes read as this program: MR130A01.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.